Quizartinib in Combination With FLAG ‐ IDA for Relapsed or Refractory Acute Myeloid Leukemia ( FLAG ‐ QUIDA ): A PETHEMA Phase I‐ II Trial
American Journal of Hematology · 2026-09 · 101 (9) · 2258-2268
DOI: 10.1002/ajh.70424 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 29.06.2026. Verfasst von Teresa Bernal und 29 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain. Hauptthemen laut MEDLINE: Phenylurea Compounds, Leukemia, Myeloid, Acute, Benzothiazoles, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daichi Sankyo.
Abstract (Originalsprache)
Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML. The FLAG‐QUIDA trial was a multicenter phase 1/2 study of quizartinib combined with FLAG‐IDA in adult patients with first R/R AML. The primary objectives were to determine the recommended phase 2 dose (RP2D) in phase 1 and to establish the complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates in phase 2. Nine patients were included in phase 1 and 52 in phase 2. Eighteen out of 61 (30%) patients were FLT3 ‐ITD‐positive. The RP2D of quizartinib was established at 60 mg/day for 14 days per 28‐day cycle. Overall, the CR/CRi rate was 56% ( n = 34), and the CR/CRi plus morphologic leukemia free state (MLFS) rate was 66% ( n = 40), without differences across genetic subgroups. Measurable residual disease negativity was achieved in 38% ( n = 13) of CR/CRi patients. Thirty‐one patients (51%) were bridged to allogeneic stem cell transplantation after FLAG‐QUIDA, 28 in CR/CRi and 3 in MLFS. Median relapse‐free survival was 17 months as compared to 7.6 months in a cohort of matched patients treated with FLAG‐IDA without quizartinib ( p = 0.028), and median overall survival was 15.8 months in the FLAG‐QUIDA cohort and 8.6 months in the matched cohort ( p = 0.09). No safety concerns were raised. FLAG‐IDA with quizartinib demonstrated promising efficacy in R/R AML, supporting future investigations. Trial Registration: EudraCT number: 2019‐001976‐12; ClinicalTrials.gov identifier: NCT04112589
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain.
- Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
- Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.
- Servicio de Hematología, Hospital Universitario San Agustín de Avilés, Avilés, Spain.
- Servicio de Hematología, Hospital U. La Fe, Valencia, Spain.
- Servicio de Hematología, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla, Sevilla, Spain.
ORCID-Profile: Teresa Bernal, Eduardo Rodríguez-Arbolí, Juan Manuel Bergua-Burgués, María Antuña-Casal, Laura Torres-Miñana, Cristina Bilbao, Pau Montesinos
Förderung
- Daichi Sankyo
Zitieren
APA
Bernal, T., Zambrano Márquez, J., Rodríguez-Veiga, R., Rodríguez-Arbolí, E., Bergua-Burgués, J. M., Vives, S., Arnán, M., Martínez Sánchez, P., Herrera-Puente, P., Serrano-López, J., Rubio, V., Marchante-Cepillo, I., Cervera-Calvo, M., Novo García, A., Fernández Martín, R., Gil Cortés, C., Rodríguez-Medina, C., Noriega-Concepción, V., Alfonso-Piérola, A., …, & Montesinos, P. (2026). Quizartinib in Combination With FLAG ‐ IDA for Relapsed or Refractory Acute Myeloid Leukemia ( FLAG ‐ QUIDA ): A PETHEMA Phase I‐ II Trial. American Journal of Hematology, 101(9), 2258-2268. https://doi.org/10.1002/ajh.70424
Vancouver
Bernal T, Zambrano Márquez J, Rodríguez-Veiga R, Rodríguez-Arbolí E, Bergua-Burgués JM, Vives S, et al. Quizartinib in Combination With FLAG ‐ IDA for Relapsed or Refractory Acute Myeloid Leukemia ( FLAG ‐ QUIDA ): A PETHEMA Phase I‐ II Trial. American Journal of Hematology. 2026;101(9):2258-2268. doi:10.1002/ajh.70424
BibTeX
@article{Bernal2026,
author = {Bernal, Teresa and Zambrano Márquez, Javier and Rodríguez-Veiga, Rebeca and Rodríguez-Arbolí, Eduardo and Bergua-Burgués, Juan Manuel and Vives, Susana and Arnán, Montserrat and Martínez Sánchez, Pilar and Herrera-Puente, Pilar and Serrano-López, Josefina and Rubio, Vicente and Marchante-Cepillo, Inmaculada and Cervera-Calvo, Marta and Novo García, Andrés and Fernández Martín, Rosa and Gil Cortés, Cristina and Rodríguez-Medina, Carlos and Noriega-Concepción, Victor and Alfonso-Piérola, Ana and Loredo, Carmen and Antuña-Casal, María and Boluda, Blanca and Cano-Ferri, Isabel and Acuña-Cruz, Evelyn and Torres-Miñana, Laura and Sánchez-García, Joaquín and Bilbao, Cristina and Gómez-Casares, Maria Teresa and Martínez Cuadrón, David and Montesinos, Pau},
title = {Quizartinib in Combination With FLAG ‐ IDA for Relapsed or Refractory Acute Myeloid Leukemia ( FLAG ‐ QUIDA ): A PETHEMA Phase I‐ II Trial},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {9},
pages = {2258--2268},
doi = {10.1002/ajh.70424}
}
EUVIMED